Does Earnings Surprise History Hold Any Clue for NYSE:KEP, NASDAQ:MRNS, NASDAQ:ALNA, NYSE:REV

0
38

KOREA ELECTRIC POWER (NYSE:KEP) EARNINGS INFORMATION (NYSE:KEP)

Korea Electric Power last announced its quarterly earnings data on December 9th, 2020. The utilities provider reported $0.77 earnings per share (EPS) for the quarter. The business earned $12.57 billion during the quarter. Korea Electric Power has generated ($1.46) earnings per share over the last year and currently has a price-to-earnings ratio of 203.8. Korea Electric Power has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, March 16th, 2021 based off prior year’s report dates.

IS KOREA ELECTRIC POWER A BUY RIGHT NOW? (NYSE:KEP)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Korea Electric Power in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” Korea Electric Power stock.
Korea Electric Power

MARINUS PHARMACEUTICALS (NASDAQ:MRNS) EARNINGS INFORMATION (NASDAQ:MRNS)

Marinus Pharmaceuticals last announced its quarterly earnings data on March 8th, 2021. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.03. Marinus Pharmaceuticals has generated ($3.96) earnings per share over the last year. Marinus Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, May 3rd, 2021 based off prior year’s report dates.

IS MARINUS PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:MRNS)

10 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Marinus Pharmaceuticals stock.
Marinus Pharmaceuticals

ALLENA PHARMACEUTICALS (NASDAQ:ALNA) EARNINGS INFORMATION (NASDAQ:ALNA)

Allena Pharmaceuticals last issued its earnings results on March 8th, 2021. The reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.05. Allena Pharmaceuticals has generated ($2.10) earnings per share over the last year. Allena Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, May 12th, 2021 based off prior year’s report dates.

IS ALLENA PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:ALNA)

5 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Allena Pharmaceuticals stock.
Allena Pharmaceuticals

REVLON EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:REV)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN REVLON? (NYSE:REV)

Wall Street analysts have given Revlon a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Revlon wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat’s top stock picks here.